Abstract
Description
The Infectives Partnering Terms and Agreements report provides comprehensive
understanding and unprecedented access to the infectives partnering deals and
agreements entered into by the worlds leading healthcare companies.
- Trends in infectives partnering deals
- Average deal terms for headline, upfront and royalty by stage of
development
- Infectives partnering agreement structure
- Infectives partnering contract documents
- Top infectives deals by value
- Most active infectives dealmakers
The Infectives Partnering Terms and Agreements report provides comprehensive
understanding and unprecedented access to the infectives partnering deals and
agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why
companies enter infectives partnering deals. The majority of deals are
discovery or development stage whereby the licensee obtains a right or an
option right to license the licensors infectives technology. These deals tend
to be multicomponent, starting with collaborative R&D, and commercialization
of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases do not.
This report contains over 2,000 links to online copies of actual infectives
deals and contract documents as submitted to the Securities Exchange
Commission by companies and their partners. Contract documents provide the
answers to numerous questions about a prospective partner's flexibility on a
wide range of important issues, many of which will have a significant impact
on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of infectives
dealmaking and business activities. Chapter 1 provides an introduction to the
report.
Chapter 2 provides an overview of the trends in infectives dealmaking since
2007 covering trends by year, deal type, stage of development, technology type
and therapeutic indication. In addition the chapter includes an analysis of
financial deal terms by stage at signing covering headline value, upfront
payment, milestone payments and royalty rates. Analysis includes median values
and distribution of values for each stage of development.
Chapter 3 provides a review of the leading infectives deals since 2007. Deals
are listed by headline value, signed by bigpharma, most active bigpharma, and
most active of all biopharma companies. Where the deal has an agreement
contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of infectives deals,
as well as contract documents available in the public domain. Where available,
each deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
Chapter 5 provides comprehensive access to all infectives deals since 2007
where a deal contract is available, providing the user with direct access to
contracts as filed with the SEC regulatory authorities. Each deal title links
via Weblink to an online version of the deal record contract document,
providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all infectives partnering
deals signed and announced since 2007. The chapter is organized by specific
infectives therapy focus. Each deal title links via Weblink to an online
version of the deal record and where available, the contract document,
providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all
infectives partnering deals signed and announced since 2007. The appendices
are organized by company A-Z, stage of development at signing, deal type
(collaborative R&D, co-promotion, licensing etc) and technology type. Each
deal title links via Weblink to an online version of the deal record and where
available, the contract document, providing easy access to each contract
document on demand.
The report also includes numerous tables and figures that illustrate the
trends and activities in infectives partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
infectives technologies and products.
Report scope
Infectives Partnering Terms and Agreements is intended to provide the reader
with an in-depth understanding and access to infectives trends and structure
of deals entered into by leading companies worldwide.
- Infectives Partnering Terms and Agreements includes:
- Trends in infectives dealmaking in the biopharma industry since 2007
- Analysis of infectives deal structure
- Access to headline, upfront, milestone and royalty data
- Access to hundreds of infectives deal contract documents
- Comprehensive access to over 2,000 infectives deal records
- The leading infectives deals by value since 2007
- Most active infectives dealmakers since 2007
In Infectives Partnering Terms and Agreements, available deals and contracts
are listed by:
- Headline value
- Upfront payment value
- Royalty rate value
- Stage of development at signing
- Deal component type
- Technology type
- Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and
where available, the contract document, providing easy access to each contract
document on demand.
The Infectives Partnering Terms and Agreements report provides comprehensive
access to available deals and contract documents for over 2,000 infectives
deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise infectives rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How aresalesand payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Benefits
Infectives Partnering Terms and Agreements provides the reader with the following key benefits:
- In-depth understanding of infectives deal trends since 2007
- Access infectives deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between infectives partner companies
- Comprehensive access to over 2,000 links to actual infectives deals
entered into by the world's biopharma companies
- Indepth review of infectives deals entered into by the leading fifty
bigpharma companies
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner infectives opportunities
- Uncover companies actively partnering infectives opportunities
Table of Contents
Executive Summary
Chapter 1 - Introduction
Chapter 2 - Trends in infectives dealmaking
- 2.1. Introduction
- 2.2. Infectives partnering over the years
- 2.3. Bigpharma infectives dealmaking activity
- 2.4. Bigpharma not active in infectives
- 2.5. Infectives partnering by deal type
- 2.6. Infectives partnering by industry sector
- 2.7. Infectives partnering by stage of development
- 2.8. Infectives partnering by technology type
- 2.9. Infectives partnering by infectives indication
- 2.10. Average deal terms for infectives
- 2.10.1 Infectives headline values
- 2.10.2 Infectives upfront payments
- 2.10.3 Infectives milestone payments
- 2.10.4 Infectives royalty rates
Chapter 3 - Leading infectives deals
- 3.1. Introduction
- 3.2. Top infectives deals by value
- 3.3. Top infectives deals involving bigpharma
Chapter 4 - Bigpharma infectives deals
- 4.1. Introduction
- 4.2. How to use bigpharma partnering deals
- 4.3. Bigpharma infectives partnering company profiles
- Abbott
- Actavis
- Actelion
- Allergan
- Amgen
- Aspen Pharmacare
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- CSL
- Daiichi Sankyo
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Endo Pharmaceuticals
- Forest Laboratories
- Galderma
- Gilead Sciences
- GlaxoSmithKline
- Grifols
- Hospira
- Johnson & Johnson
- Kyowa Hakko Kirin
- Lundbeck
- Menarini
- Merck & Co
- Merck KGaA
- Mitsubishi Tanabe
- Novartis
- Novo Nordisk
- Otsuka
- Pfizer
- Purdue
- Roche
- Sanofi
- Servier
- Shionogi
- Shire
- Takeda
- Teva
- UCB
- Valeant
- Warner Chilcott
- Watson
Chapter 5 - Infectives partnering contracts directory
- 5.1. Introduction
- 5.2. By deal type
- Asset purchase
- Assignment
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Marketing
- Material transfer
- Option
- Promotion
- Research
- Royalty financing
- Settlement
- Sub-license
- Supply
- Technology transfer
- Termination
- Warranty
- 5.3. By stage of development
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Regulatory
- Marketed
- Formulation
- 5.4. By technology type
- Adjuvant
- Animal models
- Antibodies
- Monoclonal antibodies
- Humanized mAb
- Human mAb
- Assays
- Biodefense
- Bioinformatics
- Biological compounds
- Biomarkers
- Biomaterials
- Cell culture
- Cell therapy
- Clinical testing
- Devices
- Diagnostics
- Discovery tools
- Drug delivery
- Enabling technology
- Equipment
- Facilities
- Genomics
- Industrial chemicals
- Natural product
- Oligonucleotide
- Orphan drug
- Packaging
- Pediatrics
- Peptides
- Processes
- Proteomics
- Radio/Chemo-therapy
- Recombinant DNA
- Research services
- Research supplies
- RNA therapeutics
- Screening
- Small molecules
- Software tools
- Stem cells
- Vaccines
- 5.5. By therapeutic indication
- Infectives
- Bacterial
- Anthrax
- Escherichia Coli (E-coli)
- Haemophilus influenzae type b (Hib)
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Pertussis (Whooping Cough)
- Pseudomonas aeruginosa
- Sepsis
- Tuberculosis (TB)
- Fungal
- Onychomycosis (Nail infection)
- Parasitic
- Tropical
- Dengue fever
- Malaria
- Viral
- Common cold
- Ebola
- Foot and mouth disease
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Herpes simplex
- HIV
- Influenza
- H5N1 (Avian Flu)
- Japanese encephalitis
- Respiratory syncytial virus (RSV)
Chapter 6 - Infectives dealmaking by indication
- 6.1. Introduction
- 6.2. Deals by therapeutic indication
- Infectives
- Bacterial
- Anthrax
- Campylobacter Jejuni
- Clostridium difficile
- Diphtheria
- Escherichia Coli (E-coli)
- Group A Streptococcus
- Group B Streptococcus
- Haemophilus influenzae type b (Hib)
- Helicobacter Pylori
- Lyme disease
- Methicillin-resistant Staphylococcus aureus (MRSA)
- Mycobacterium avium
- Pertussis (Whooping Cough)
- Pseudomonas aeruginosa
- Salmonella
- Sepsis
- Tetanus
- Tuberculosis (TB)
- Fungal
- Nail Psoriasis
- Onychomycosis (Nail infection)
- Parasitic
- Tropical
- African trypanosomiasis (Sleeping sickness)
- Dengue fever
- Malaria
- Yellow fever
- Viral
- Common cold
- Cytomegalovirus
- Ebola
- FIV
- Foot and mouth disease
- Hepatitis
- Hepatitis A
- Hepatitis B
- Hepatitis C
- Hepatitis D
- Herpes simplex
- HIV
- Influenza
- H1N1 (Swine Flu)
- H5N1 (Avian Flu)
- Japanese encephalitis
- Polio
- Respiratory syncytial virus (RSV)
Chapter 7 - Partnering resource center
- 7.1. Online partnering
- 7.2. Partnering events
- 7.3. Further reading on dealmaking
About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
Appendix
- Appendix 1 - Directory of infectives deals by company A-Z 2007-2013
- Appendix 2 - Directory of infectives deals by deal type 2007-2013
- Appendix 3 - Directory of infectives deals by stage of development
2007-2013
- Appendix 4 - Directory of infectives deals by technology type 2007-2013
- Appendix 5 - Deal type definitions
Table of figures
- Figure 1: Infectives partnering since 2007
- Figure 2: Bigpharma - top 50 - infectives deals 2007 to 2013
- Figure 3: Bigpharma infectives deal frequency - 2007 to 2013
- Figure 4: Inactive bigpharma in infectives 2007-2013
- Figure 5: Infectives partnering by deal type since 2007
- Figure 6: Infectives partnering by industry sector since 2007
- Figure 7: Infectives partnering by stage of development since 2007
- Figure 8: Infectives partnering by technology type since 2007
- Figure 9: Infectives partnering by infective target since 2007
- Figure 10: Infectives deals with a headline value
- Figure 11: Infectives deal headline value distribution, US$million -
discovery stage
- Figure 12: Infectives deal headline value distribution, US$million -
preclinical stage
- Figure 13: Infectives deal headline value distribution, US$million - phase
I stage
- Figure 14: Infectives deal headline value distribution, US$million - phase
II stage
- Figure 15: Infectives deal headline value distribution, US$million - phase
III stage
- Figure 16: Infectives deal headline value distribution, US$million -
regulatory stage
- Figure 17: Infectives deal headline value distribution, US$million -
marketed stage
- Figure 18: Summary median headline value by stage of development, 2005-2013
- Figure 19: Infectives deals with upfront payment values
- Figure 20: Infectives deal upfront payment distribution, US$million -
discovery stage
- Figure 21: Infectives deal upfront payment distribution, US$million -
preclinical stage
- Figure 22: Infectives deal upfront payment distribution, US$million -
phase I stage
- Figure 23: Infectives deal upfront payment distribution, US$million -
phase II stage
- Figure 24: Infectives deal upfront payment distribution, US$million -
phase III stage
- Figure 25: Infectives deal upfront payment distribution, US$million -
regulatory stage
- Figure 26: Infectives deal upfront payment distribution, US$million -
marketed stage
- Figure 27: Summary median upfront payments by stage of development,
2005-2013
- Figure 28: Infectives deals with milestone payments
- Figure 29: Infectives deal milestone distribution, US$million - discovery
stage
- Figure 30: Infectives deal milestone distribution, US$million -
preclinical stage
- Figure 31: Infectives deal milestone distribution, US$million - phase I
stage
- Figure 32: Infectives deal milestone distribution, US$million - phase II
stage
- Figure 33: Infectives deal milestone distribution, US$million - phase III
stage
- Figure 34: Infectives deal milestone distribution, US$million - regulatory
stage
- Figure 35: Infectives deal milestone distribution, US$million - marketed
stage
- Figure 36: Infectives deals with royalty rates, %
- Figure 37: Infectives deal royalty rate distribution, US$million -
discovery stage
- Figure 38: Infectives deal royalty rate distribution, US$million -
preclinical stage
- Figure 39: Infectives deal royalty rate distribution, US$million - phase I
stage
- Figure 40: Infectives deal royalty rate distribution, US$million - phase
II stage
- Figure 41: Infectives deal royalty rate distribution, US$million - phase
III stage
- Figure 42: Infectives deal royalty rate distribution, US$million -
regulatory stage
- Figure 43: Infectives deal royalty rate distribution, US$million -
marketed stage
- Figure 44: Summary median royalty rate by stage of development, 2005-2013
- Figure 45: Top infectives deals by value since 2007
- Figure 46: Top infectives deals signed by bigpharma value since 2007
- Figure 47: Online partnering resources
- Figure 48: Forthcoming partnering events
